Acitretin
- Generic Name
- Acitretin
- Brand Names
- Soriatane
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26O3
- CAS Number
- 55079-83-9
- Unique Ingredient Identifier
- LCH760E9T7
- Background
An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate.
- Indication
For the treatment of severe psoriasis in adults.
- Associated Conditions
- Keratinization disorders, Severe Psoriasis
- Associated Therapies
- -
Systemic Treatment Options for Generalized Lichen Planus
- Conditions
- Interventions
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Sheikh Zayed Medical College
- Target Recruit Count
- 124
- Registration Number
- NCT06739551
- Locations
- 🇵🇰
Sheikh zayed Medical College and Hospital, Rahim Yar Khan, Punjab, Pakistan
Omentin-1 Level in Psoriatic Patients Treated With Narrowband Ultraviolet B Phototherapy Versus Acitretin
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- Mahmoud Ahmed Ali Ahmed
- Target Recruit Count
- 60
- Registration Number
- NCT05203354
- Locations
- 🇪🇬
Faculty of medicine - Aswan university, Aswan, Egypt
Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2020-09-03
- Last Posted Date
- 2022-11-25
- Lead Sponsor
- Singapore General Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04537689
- Locations
- 🇸🇬
Singapore General Hospital, Outram Park, Singapore
Combined Effect of Acitretin and Narrow Band Ultraviolet B on Vitiligo Repigmentation
- Conditions
- Interventions
- First Posted Date
- 2020-01-28
- Last Posted Date
- 2021-07-22
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 20
- Registration Number
- NCT04245319
- Locations
- 🇪🇬
Cairo University, Cairo, Egypt
Outcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2022-11-25
- Lead Sponsor
- Singapore General Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04239859
- Locations
- 🇸🇬
Singapore General Hospital, Outram Park, Singapore
RA Effect on Cell Surface Molecules in Vivo
- First Posted Date
- 2018-11-27
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- Ottawa Hospital Research Institute
- Registration Number
- NCT03753867
Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation
- First Posted Date
- 2015-01-01
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- University Hospitals Cleveland Medical Center
- Target Recruit Count
- 26
- Registration Number
- NCT02330380
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Addition of Excimer Laser to Treatment With Acitretin Tablets for Psoriasis of the Palms and Soles
- Conditions
- Interventions
- First Posted Date
- 2014-07-04
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 2
- Registration Number
- NCT02181790
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2018-12-26
- Lead Sponsor
- University of Arizona
- Target Recruit Count
- 2
- Registration Number
- NCT02050321
- Locations
- 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis
- Conditions
- First Posted Date
- 2013-03-18
- Last Posted Date
- 2017-08-11
- Lead Sponsor
- Jochen Schmitt.
- Target Recruit Count
- 1
- Registration Number
- NCT01812954
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.